In reply

Liam D. A. Paget; Gustaaf Reurink; Johannes L. Tol

doi:https://doi.org/10.1001/jama.2021.24757

In reply

Liam D. A. Paget, Gustaaf Reurink, Johannes L. Tol

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	781
Number of pages	1
Journal	JAMA
Volume	327
Issue number	8
DOIs	https://doi.org/10.1001/jama.2021.24757
Publication status	Published - 22 Feb 2022

Access to Document

https://doi.org/10.1001/jama.2021.24757

Cite this

@article{2556fb6c9f89469fbc0e8e486cfd9e71,

title = "In reply",

author = "Paget, {Liam D. A.} and Gustaaf Reurink and Tol, {Johannes L.}",

note = "Funding Information: Funding/Support: This work was supported in part by the National Institute of Allergy and Infectious Diseases (grants R01AI120938, R01AI128779, and T32AI102623) and the National Institute on Drug Abuse (grant F31DA054849) of the National Institutes of Health. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. 1. Peters PJ, Pontones P, Hoover KW, et al; Indiana HIV Outbreak Investigation Team. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229-239. doi:10.1056/NEJMoa1515195 2. Liang TJ, Ward JW. Hepatitis C in injection-drug users—a hidden danger of the opioid epidemic. N Engl J Med. 2018;378(13):1169-1171. doi:10.1056/ NEJMp1716871 3. US Department of Health and Human Services. HIV National Strategic Plan for the United States: A Roadmap to End the Epidemic 2021-2025. Published January 15, 2021. Accessed January 11, 2022. https://hivgov-prod-v3.s3. amazonaws.com/s3fs-public/HIV-National-Strategic-Plan-2021-2025.pdf 4. McNamara KF, Biondi BE, Hern{\'a}ndez-Ram{\'i}rez RU, Taweh N, Grimshaw AA, Springer SA. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. 2021;8(8):ofab289. doi:10.1093/ofid/ofab289 5. Bachhuber MA, Cunningham CO. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. JAMA. 2013;310(24):2671-2672. doi:10.1001/jama. 2013.278456 6. Lerner AM, Fauci AS. Opioid injection in rural areas of the United States: a potential obstacle to ending the HIV epidemic. JAMA. 2019;322(11):1041-1042. doi:10.1001/jama.2019.10657 Funding Information: Author Affiliations: Amsterdam UMC, Department of Orthopedic Surgery, Amsterdam, the Netherlands (Paget, Reurink); Amsterdam UMC, Academic Center for Evidence-Based Sports Medicine (ACES), Amsterdam, the Netherlands (Tol). Corresponding Author: Liam D. A. Paget, MD, Amsterdam UMC, University of Amsterdam, Department of Orthopedic Surgery, Amsterdam Movement Sciences, PO Box 22660, 1100 DD Amsterdam, the Netherlands (l.d.paget@amsterdamumc.nl). Conflict of Interest Disclosures: Drs Paget, Reurink, and Tol reported receiving an institutional grant from the Dutch Arthritis Society and institutional nonfinancial support from Arthrex (Hettich centrifuge on loan) during the conduct of the study.",

year = "2022",

month = feb,

day = "22",

doi = "https://doi.org/10.1001/jama.2021.24757",

language = "English",

volume = "327",

pages = "781",

journal = "JAMA",

issn = "0098-7484",

publisher = "American Medical Association",

number = "8",

}

TY - JOUR

T1 - In reply

AU - Paget, Liam D. A.

AU - Reurink, Gustaaf

AU - Tol, Johannes L.

N1 - Funding Information: Funding/Support: This work was supported in part by the National Institute of Allergy and Infectious Diseases (grants R01AI120938, R01AI128779, and T32AI102623) and the National Institute on Drug Abuse (grant F31DA054849) of the National Institutes of Health. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. 1. Peters PJ, Pontones P, Hoover KW, et al; Indiana HIV Outbreak Investigation Team. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229-239. doi:10.1056/NEJMoa1515195 2. Liang TJ, Ward JW. Hepatitis C in injection-drug users—a hidden danger of the opioid epidemic. N Engl J Med. 2018;378(13):1169-1171. doi:10.1056/ NEJMp1716871 3. US Department of Health and Human Services. HIV National Strategic Plan for the United States: A Roadmap to End the Epidemic 2021-2025. Published January 15, 2021. Accessed January 11, 2022. https://hivgov-prod-v3.s3. amazonaws.com/s3fs-public/HIV-National-Strategic-Plan-2021-2025.pdf 4. McNamara KF, Biondi BE, Hernández-Ramírez RU, Taweh N, Grimshaw AA, Springer SA. A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes. Open Forum Infect Dis. 2021;8(8):ofab289. doi:10.1093/ofid/ofab289 5. Bachhuber MA, Cunningham CO. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs. JAMA. 2013;310(24):2671-2672. doi:10.1001/jama. 2013.278456 6. Lerner AM, Fauci AS. Opioid injection in rural areas of the United States: a potential obstacle to ending the HIV epidemic. JAMA. 2019;322(11):1041-1042. doi:10.1001/jama.2019.10657 Funding Information: Author Affiliations: Amsterdam UMC, Department of Orthopedic Surgery, Amsterdam, the Netherlands (Paget, Reurink); Amsterdam UMC, Academic Center for Evidence-Based Sports Medicine (ACES), Amsterdam, the Netherlands (Tol). Corresponding Author: Liam D. A. Paget, MD, Amsterdam UMC, University of Amsterdam, Department of Orthopedic Surgery, Amsterdam Movement Sciences, PO Box 22660, 1100 DD Amsterdam, the Netherlands (l.d.paget@amsterdamumc.nl). Conflict of Interest Disclosures: Drs Paget, Reurink, and Tol reported receiving an institutional grant from the Dutch Arthritis Society and institutional nonfinancial support from Arthrex (Hettich centrifuge on loan) during the conduct of the study.

PY - 2022/2/22

Y1 - 2022/2/22

UR - http://www.scopus.com/inward/record.url?scp=85125020435&partnerID=8YFLogxK

U2 - https://doi.org/10.1001/jama.2021.24757

DO - https://doi.org/10.1001/jama.2021.24757

M3 - Comment/Letter to the editor

C2 - 35191929

SN - 0098-7484

VL - 327

SP - 781

JO - JAMA

JF - JAMA

IS - 8

ER -

In reply

Access to Document

Other files and links

Cite this